Relationship Between Body Mass Index and Proteinuria in Hypertensive Nephrosclerosis: Results From the African American Study of Kidney Disease and Hypertension (AASK) Cohort

被引:36
|
作者
Toto, Robert D. [1 ]
Greene, Tom [2 ]
Hebert, Lee A. [3 ]
Hiremath, Leena [3 ]
Lea, Janice P. [4 ]
Lewis, Julia B. [5 ]
Pogue, Velvie [6 ]
Sika, Mohammed [5 ]
Wang, Xuelei [7 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[2] Univ Utah, Sch Med, Salt Lake City, UT USA
[3] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
[4] Emory Univ, Atlanta, GA 30322 USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Harlem Hosp Med Ctr, New York, NY 10037 USA
[7] Cleveland Clin, Cleveland, OH 44106 USA
基金
美国国家卫生研究院;
关键词
Obesity; body mass index; chronic kidney disease; proteinuria; hypertension; URINARY ALBUMIN EXCRETION; STAGE RENAL-DISEASE; INSULIN-RESISTANCE; METABOLIC SYNDROME; BLOOD-PRESSURE; RISK-FACTORS; US ADULTS; URIC-ACID; OBESITY; CKD;
D O I
10.1053/j.ajkd.2010.05.016
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Few studies have examined the association between obesity and markers of kidney injury in a chronic kidney disease population. We hypothesized that obesity is independently associated with proteinuria, a marker of chronic kidney disease progression. Study Design: Observational cross-sectional analysis. Setting & Participants: Post hoc analysis of baseline data for 652 participants in the African American Study of Kidney Disease (AASK). Predictors: Obesity, determined using body mass index (BMI). Measurements & Outcomes: Urine total protein-creatinine ratio and albumin-creatinine ratio measured in 24-hour urine collections. Results: AASK participants had a mean age of 60.2 +/- 10.2 years and serum creatinine level of 2.3 +/- 1.5 mg/dL; 61.3% were men. Mean BMI was 31.4 +/- 7.0 kg/m(2). Approximately 70% of participants had a daily urine total protein excretion rate <300 mg/d. In linear regression analyses adjusted for sex, each 2-kg/m(2) increase in BMI was associated with a 6.7% (95% CI, 3.2-10.4) and 9.4% (95% CI, 4.9-14.1) increase in urine total protein-creatinine and urine albumin-creatinine ratios, respectively. In multivariable models adjusting for age, sex, systolic blood pressure, serum glucose level, uric acid level, and creatinine level, each 2-kg/m2 increase in BMI was associated with a 3.5% (95% CI, 0.4-6.7) and 5.6% (95% CI, 1.5-9.9) increase in proteinuria and albuminuria, respectively. The interaction between older age and BMI was statistically significant, indicating that this relationship was driven by younger AASK participants. Limitations: May not generalize to other populations; cross-sectional analysis precludes statements regarding causality. Conclusions: BMI is associated independently with urine total protein and albumin excretion in African Americans with hypertensive nephrosclerosis, particularly in younger patients. Am J Kidney Dis 56: 896-906. (C) 2010 by the National Kidney Foundation, Inc.
引用
收藏
页码:896 / 906
页数:11
相关论文
共 50 条
  • [21] The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease - Results of the African American study of kidney disease and hypertension
    Lea, J
    Greene, T
    Hebert, L
    Lipkowitz, M
    Massry, S
    Middleton, J
    Rostand, SG
    Miller, E
    Smith, W
    Bakris, GL
    ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (08) : 947 - 953
  • [22] Associations of Baseline and Longitudinal Serum Uromodulin With Kidney Failure and Mortality: Results From the African American Study of Kidney Disease and Hypertension (AASK) Trial
    Chen, Teresa K.
    Estrella, Michelle M.
    Appel, Lawrence J.
    Surapaneni, Aditya L.
    Kottgen, Anna
    Obeid, Wassim
    Parikh, Chirag R.
    Grams, Morgan E.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (01) : 71 - 78
  • [23] Implementing the medical dictionary for regulatory activities (MEDDRA) in the cohort phase of the African American study of kidney disease and hypertension (AASK)
    Gassman, J
    Tuason, L
    Brittain, K
    Litowitz, H
    Middleton, J
    Wiggins, K
    CONTROLLED CLINICAL TRIALS, 2003, 24 : 170S - 171S
  • [24] Baseline predictors of renal disease progression in the African American (AA) study of hypertension and kidney disease (AASK)
    Norris, K
    Greene, T
    Kopple, J
    Lea, J
    Lipkowitz, M
    Miller, E
    Richardson, A
    Rostand, S
    Wang, XL
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 190A - 190A
  • [25] The relationship between achieved blood pressure (BP) and renal outcomes in the African American study of kidney disease (AASK).
    Appel, LJ
    Bakris, G
    Douglas-Baltimore, J
    Greene, T
    Kopple, J
    Massry, S
    Wang, XL
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 423A - 423A
  • [26] APOL1 Genotype, Proteinuria, and the Risk of Kidney Failure: A Secondary Analysis of the AASK (African American Study of Kidney Disease and Hypertension) and CRIC (Chronic Renal Insufficiency Cohort) Studies
    Nguyen, Anthony
    Suen, Sze-chuan
    Lin, Eugene
    KIDNEY MEDICINE, 2022, 4 (12)
  • [27] RECRUITMENT IN THE AFRICAN-AMERICAN STUDY OF KIDNEY-DISEASE AND HYPERTENSION (AASK) PILOT-STUDY
    WHELTON, P
    LEE, J
    KOPPLE, J
    FAULKNER, M
    CHARLESTON, J
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 570 - 570
  • [28] Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study
    Wright, JT
    Kusek, JW
    Toto, RD
    Lee, JY
    Agodoa, LY
    Kirk, KA
    Randall, OS
    Glassock, R
    CONTROLLED CLINICAL TRIALS, 1996, 17 (04): : S3 - S16
  • [29] Baseline echocardiographic characteristics and the predictors of LV mass in the African American study of kidney disease (AASK)
    Ilic, V
    Peterson, G
    Vagaonescu, T
    Gabriel, A
    Kendrick, C
    Phillips, RA
    AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) : 27A - 28A
  • [30] Adding ambulatory blood pressure monitoring (ABPM) to the African American study of kidney disease and hypertension (AASK)
    Gassman, J
    Charleston, J
    Gabriel, A
    Hiremath, L
    Brittain, K
    Phillips, R
    Appel, L
    CONTROLLED CLINICAL TRIALS, 2003, 24 : 175S - 175S